Plus Therapeutics Reports Q3 Revenue of $0.72 Million and GAAP EPS of -$1.14
Plus Therapeutics (CNSY) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $1.14. The company's revenue for the quarter reached $0.72 million, representing a significant year-over-year decline of 48.6%. The substantial drop in revenue suggests ongoing challenges in scaling commercial operations or shifts in product demand compared to the previous year. Investors will likely monitor how these declining revenues and continued net losses impact the company's cash runway and long-term development goals.
Tickers: $PSTV
Topics: earnings GAAP EPS revenue decline